Abivax (ABVX) Common Equity (2023 - 2026)

Abivax's Common Equity history runs 4 years deep, the most recent figure standing at $502.9 million for Q1 2026.

• On a quarterly basis, Common Equity rose 7353.3% year-over-year to $502.9 million in Q1 2026; TTM through Mar 2026 was $502.9 million, a 7353.3% increase from a year earlier, with the FY2025 full-year figure at $529.9 million, up 1105.83% from the prior year.
• Common Equity slipped to $502.9 million in Q1 2026 per ABVX's latest filing, from $529.9 million in the prior quarter.
• Across five years, Common Equity topped out at $597.7 million in Q3 2025 and bottomed at -$54.7 million in Q2 2025.
• The 4-year median for Common Equity is $173.5 million (2023), against an average of $244.9 million.
• Across the five-year window, Common Equity plunged 140.13% in 2025 and jumped 7353.3% in 2026, its largest moves.
• Year by year, Common Equity stood at $210.9 million in 2023, then tumbled by 79.43% to $43.4 million in 2024, then jumped by 1121.34% to $529.9 million in 2025, then slipped by 5.08% to $502.9 million in 2026.
• Per Business Quant, the three latest ABVX Common Equity figures stand at $502.9 million (Q1 2026), $529.9 million (Q4 2025), and $597.7 million (Q3 2025).